文献速递脑血管病神经重症与神经感染

常压高氧联合血管内取栓治疗6至24小时急性卒中:IIb期随机试验

Adjunctive Normobaric Hyperoxia With Endovascular Thrombectomy for Acute Stroke at 6 to 24 Hours: A Phase IIb Randomized Trial.
PubMed 文献 · Stroke · 2026-07-06

这项在中国2个学术性综合卒中中心开展的IIb期随机、评估者盲法对照试验,将发病6至24小时的前循环大血管闭塞患者1:1分配至EVT+NBO或单纯EVT。NBO组在再通前开始经面罩给予100%氧气10 L/min持续4小时。结果显示NBO+EVT组早期神经功能改善率显著更高(35%对19%;校正OR 2.86 [95%CI 1.12-7.45]),24-48小时梗死体积更小,90天mRS分布数值上倾向NBO+EVT但未达统计学显著,安全性结局无差异。

要点

  • 发病6-24小时前循环大血管闭塞患者,EVT联合NBO较单纯EVT显著提高早期神经功能改善率。
  • NBO+EVT组24-48小时中位梗死体积显著小于单纯EVT组。
  • 90天mRS分布数值上倾向NBO+EVT但未达统计学显著,安全性结局无差异。

核心结论

  • 在发病6至24小时接受治疗的急性缺血性卒中患者中,辅助NBO联合EVT是安全的,并改善了早期神经功能结局和梗死体积,支持在更大规模试验中进一步评估。

研究设计与样本

  • IIb期随机、评估者盲法、对照试验,在中国2个学术性综合卒中中心开展。
  • 筛查324例,随机分配120例至NBO+EVT或单纯EVT(每组60例,意向性治疗人群)。
  • 纳入年龄≥18岁、前循环大血管闭塞、发病6至24小时的急性缺血性卒中患者。
  • NBO组经面罩给予100%氧气10 L/min持续4小时,从再通前开始。
  • 主要终点为早期神经功能改善(24小时NIHSS评分降低≥30%),采用校正回归模型控制预设预后协变量。

主要发现

  • NBO+EVT组早期神经功能改善率显著高于单纯EVT组(35%对19%;校正OR 2.86 [95%CI 1.12-7.45])。
  • 24至48小时中位梗死体积NBO+EVT组显著更小(20.5 [IQR 13.6-31.8] mL对32.3 [IQR 22.7-44.5] mL;P=0.001)。
  • 90天mRS分布数值上倾向NBO+EVT但未达统计学显著(中位mRS 2 [IQR 1-3]对3 [IQR 1-4];校正共同OR 1.52 [95%CI 0.87-2.63])。
  • 死亡率、症状性颅内出血、早期神经功能恶化和复发性卒中两组间无差异。

关键数值与推荐

  • 早期神经功能改善定义为24小时NIHSS评分降低≥30%。
  • NBO方案为经面罩100%氧气10 L/min持续4小时,从再通前开始。
  • 主要分析采用校正二项回归模型,控制年龄、性别、静脉溶栓和闭塞部位。
  • 90天mRS偏移采用校正有序逻辑回归模型分析。

临床怎么用

  • 对于发病6至24小时的前循环大血管闭塞患者,EVT联合NBO可能作为安全的辅助策略改善早期神经功能和减少梗死体积。
  • NBO操作简单(面罩吸氧10 L/min持续4小时),但90天功能结局获益尚未证实,需更大规模试验验证。

局限性

  • IIb期探索性试验,样本量120例,90天mRS差异未达统计学显著。
  • 仅在2个中国中心开展,外推性受限。
  • 评估者盲法,但NBO干预可能影响盲法实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Normobaric hyperoxia (NBO) is a simple neuroprotective strategy that may augment endovascular thrombectomy (EVT) in acute ischemic stroke. We evaluated the safety and preliminary efficacy of NBO plus EVT in patients with large-vessel occlusion presenting 6 to 24 hours after onset. METHODS: In this phase IIb, randomized, assessor-blinded, controlled trial conducted at 2 academic comprehensive stroke centers in China, patients aged ≥18 years with anterior circulation large-vessel occlusion presenting 6 to 24 hours after acute ischemic stroke onset were assigned 1:1 to EVT+NBO or EVT alone. The NBO group received 100% oxygen via a face mask at 10 L/min for 4 hours, starting before recanalization. The primary end point was early neurological improvement (≥30% reduction in the National Institutes of Health Stroke Scale score at 24 hours). Primary analyses used adjusted regression models controlling for prespecified prognostic covariates. Secondary end points included infarct volume at 24 to 48 hours and the modified Rankin Scale score at 90 days. Safety outcomes were mortality, intracranial hemorrhage, and symptomatic intracranial hemorrhage. Analyses followed the intention-to-treat principle. Early neurological improvement was analyzed using an adjusted binomial regression model, and the 90-day modified Rankin Scale shift was analyzed using an adjusted ordinal logistic regression model, controlling for age, sex, intravenous thrombolysis, and occlusion site. RESULTS: Between October 2021 and October 2023, 324 patients were screened, and 120 were randomly assigned to NBO+EVT or EVT alone (60 patients per group; intention-to-treat population). The median baseline National Institutes of Health Stroke Scale score was 12 (interquartile range [IQR], 8-15) in the NBO+EVT group and 12 (IQR, 9-16) in the EVT-alone group. The median time from stroke onset to randomization was 10.0 hours (IQR, 7.0-14.4) and 9.9 hours (IQR, 8.4-14.8), respectively. The EVT+NBO group demonstrated a significantly higher rate of early neurological improvement compared with EVT alone (35% versus 19%; adjusted odds ratio, 2.86 [95% CI, 1.12-7.45]). The median infarct volume at 24 to 48 hours was significantly smaller in the EVT+NBO group (20.5 [IQR, 13.6-31.8] mL versus 32.3 [IQR, 22.7-44.5] mL; P=0.001). At 90 days, the modified Rankin Scale distribution numerically favored NBO+EVT but was not statistically significant (median modified Rankin Scale, 2 [IQR, 1-3] versus 3 [IQR, 1-4]; adjusted common odds ratio, 1.52 [95% CI, 0.87-2.63]). Mortality, symptomatic intracranial hemorrhage, early neurological deterioration, and recurrent stroke did not differ between groups. CONCLUSIONS: In patients with acute ischemic stroke treated 6 to 24 hours after onset, adjunctive NBO with EVT was safe and improved early neurological outcomes and infarct volume, supporting further evaluation in larger trials. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05128422.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Li W, Hu W, Wang S, et al. Adjunctive Normobaric Hyperoxia With Endovascular Thrombectomy for Acute Stroke at 6 to 24 Hours: A Phase IIb Randomized Trial. Stroke. 2026. PMID: 42403344. doi:10.1161/STROKEAHA.125.055019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。